Indication
Anaplastic Large-cell Lymphoma
1 clinical trial
1 product
Clinical trial
A Phase 1/2 Study of Brentuximab Vedotin (SGN-35) in Pediatric Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma or Hodgkin LymphomaStatus: Completed, Estimated PCD: 2016-10-12
Product
Brentuximab vedotin